ArticleAmerican journal of clinical and experimental urology2019
Bioinformatics analyses of publicly available NEPCa datasets.
Article in American journal of clinical and experimental urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- A Neuroendocrine Differentiation-related Molecular Model for Prognosis Prediction in Prostate Cancer Patients.Current medicinal chemistry · 2026Article
- OPRK1 drives SLC9A3R1 progression to neuroendocrine prostate cancer.Cell death & disease · 2025Article
- Multi-omics analysis constructs a novel neuroendocrine prostate cancer classifier and classification system.Scientific reports · 2025Article
- The role of transcription factors in prostate cancer progression.Molecules and cells · 2025Review
- CDHu40: a novel marker gene set of neuroendocrine prostate cancer.Briefings in bioinformatics · 2024Article
- Systematic Multi-Omics Investigation of Androgen Receptor Driven Gene Expression and Epigenetics changes in Prostate Cancer.bioRxiv : the preprint server for biology · 2024Article
- Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review.Cancers · 2024Review
- Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.Oncogene · 2022Article
- Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation.Molecular cancer therapeutics · 2022Article
- Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.Journal of experimental & clinical cancer research : CR · 2022Review
- TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p.Cancers · 2021Article
- Review
- Review
- Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression.Scientific reports · 2021Article
- The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.Prostate cancer and prostatic diseases · 2020Article
- MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.Oncogene · 2020Article
- Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.International journal of molecular sciences · 2020Article
- FOXA2 promotes prostate cancer growth in the bone.American journal of translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Gene expression profiles are valuable resources for the identification of key players that driver disease progression. However, neuroendocrine prostate cancer (NEPCa) specimens are rare, limiting research on this aggressive disease. In this study, we generated a 12-gene signature of NEPCa and used this signature to differentiate NEPCa from prostate adenocarcinoma (AdPCa) samples in publicly available datasets. From these samples, we identified genes that were differentially expressed in NEPCa and AdPCa. Gene ontology and network analyses revealed key players in the pathogenesis of NEPCa, including E2Fs, members of MHC class II, and factors involved in neuron differentiation, neurogenesis, and stem cell signaling. In conclusion, we identified a 12-gene signature of NEPCa and found pathways that are important for the pathologic development of NEPCa.
Indexed as
Identifiers
31763364PMC6872473W2997758429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.